Berobenatide, also referenced as PF-07976094 or PF'3944, is Pfizer's ultra-long-acting injectable GLP-1 receptor agonist peptide, engineered for once-monthly dosing through a 0.5 mL low-volume subcutaneous injection. The asset entered Pfizer's pipeline through the $4.9 billion acquisition of Metsera, completed earlier in 2026, and now anchors a planned obesity expansion spanning more than 20 trials.
The Phase 2b VESPER program delivered Pfizer's first competitive data at ADA 2026. VESPER-1 showed up to 15.9% mean weight loss at 32 weeks on 2.4 mg weekly dosing with no plateau observed and a tolerability profile that BioPharma Dive's wrap called 'foundational.' Pfizer plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of berobenatide in chronic weight management plus comorbidities such as knee osteoarthritis and obstructive sleep apnea. The monthly-dosing differentiation positions berobenatide against once-weekly incumbents on adherence, alongside Amgen's MariTide and Ascletis's ASC30.
Stories here cover berobenatide trial readouts and Pfizer's post-Metsera obesity strategy. See #pfizer, #metsera, and #monthly-glp-1 for adjacent threads.
Pfizer (NYSE: PFE) named Danna Breen Vice President and head of obesity discovery on Monday July 13, 2026, following the departure of longtime scientific leader Kendra Bence. Bence had led internal medicine research across metabolic dysfunction-associated steatohepatitis (formerly known as NASH) and obesity discovery at Pfizer's Kendall Square research site for more than a decade, and described the role as 'the absolute privilege of my career' when announcing her exit. Breen advanced through multiple roles at Pfizer including Research Associate, Fellow, Senior Principal Scientist, Principal Scientist, and Senior Scientist, working on novel obesity drug targets and research collaborations. The role transition arrives as Pfizer's obesity portfolio expands substantially: the monthly GLP-1 receptor agonist berobenatide (PF-3944) is advancing through 10 planned Phase 3 studies presented at ADA 2026 in June, and the November 2025 $10 billion Metsera acquisition brought in the amylin peptide MET-233i (positive Phase 1 data supporting monthly dosing). Endpoints News concurrently reported AI startup Xaira making its own leadership adjustments as the sector's talent map continues to reshape.
Pfizer announced on June 18, 2026 (8-K filed) that Chief Financial Officer Dave Denton will step down from his role and leave the company on August 15 for a professional opportunity outside the pharmaceutical industry in consumer goods. Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business (joined Pfizer in 2005, current role since 2022), was named Interim CFO effective August 16 while Pfizer conducts internal and external search. The same June 18 8-K reaffirmed 2026 guidance: revenues of $59.5-62.5B and adjusted diluted EPS of $2.80-3.00. Pfizer also presented detailed berobenatide (PF'3944) Phase 2b VESPER-1/-2/-3 data at the ADA Scientific Sessions June 6 supporting monthly dosing for the first-in-class GLP-1 RA peptide and confirmed plans for 10 Phase 3 studies in 2026 as part of a 20+ obesity-trial program. PFE stock dropped 3% on the CFO surprise.
Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.
Pfizer presented Phase 2b VESPER-1 data for berobenatide (PF-07976094 / PF'3944), the ultra-long-acting injectable GLP-1 peptide engineered for monthly dosing through a 0.5 mL low-volume injection. At ADA 2026, the 2.4 mg weekly dose drove up to 15.9% mean weight loss at 32 weeks with no plateau across the VESPER program, plus improved glycemic control and favorable tolerability. Pfizer plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of berobenatide in chronic weight management, knee osteoarthritis, and obstructive sleep apnea. The asset entered Pfizer's pipeline through the $4.9 billion Metsera acquisition.
The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.